Immunomodulatory and anti-inflammatory effects of chondroitin sulphate

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 A, 2009, Pages 1451-1463

  Du Souich, Patrick ^a   García, Antonio G ^b   Vergés, Josep ^c   Montell, Eulàlia ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c BIOIBERICA SA   (Spain)

Author keywords

Alzheimer's disease; Atherosclerosis; Autoimmune diseases; Chondroitin sulphate; Inflammation; Inflammatory bowel disease; Multiple sclerosis; Parkinson disease; Psoriasis

Indexed keywords

EID: 70349335800     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00826.x     Document Type: Article

References (152)

1. Martel-Pelletier J, Boileau C, Pelletier JP, et al. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol. 2008 22 : 351 384.
2. Hardingham T. Extracellular matrix and pathogenic mechanisms in osteoarthritis. Curr Rheumatol Rep. 2008 10 : 30 6.
3. Bali JP, Cousse H, Neuzil E. Biochemical basis of the pharmacologic action of chon-droitin sulfates on the osteoarticular system. Semin Arthritis Rheum. 2001 31 : 58 68.
4. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007 96 : 3168 3180.
5. Domagala F, Martin G, Bogdanowicz P, et al. Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: potential mechanism for Diacerein effects in osteoarthritis. Biorheology. 2006 43 : 577 587.
6. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 2006 14 : 839 848.
7. Agarwal S, Deschner J, Long P, et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum. 2004 50 : 3541 3548.
8. Liacini A, Sylvester J, Li WQ, et al. Inhibition of interleukin-1- stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002 21 : 251 262.
9. Lianxu C, Hongti J, Changlong Y. NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage. 2006 14 : 467 476.
10. Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collage-nase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of colla-genase 1 and collagenase 3. Arthritis Rheum. 2000 43 : 801 811.
11. Wada Y, Shimada K, Sugimoto K, et al. Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metallo-proteinase-1,-13 and prostaglandin E2 production in human chondrocytes. Int Immunopharmacol. 2006 6 : 144 155.
12. Berenbaum F, Humbert L, Bereziat G, et al. Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phos-pholipase A2 via ATP in articular chondro-cytes. J Biol Chem. 2003 278 : 13680 13687.
13. Wen D, Nong Y, Morgan JG, et al. A Selective small molecule IkappaB inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibrob-last-like synoviocytes, chondrocytes and mast cells. J Pharmacol Exp Ther. 2006 317 : 989 1001.
14. Jomphe C, Gabriac M, Hale TM, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondro-cytes. Basic Clin Pharmacol Toxicol. 2008 102 : 59 65.
15. Benito MJ, Veale DJ, FitzGerald O, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005 64 : 1263 1267.
16. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003 423 : 356 361.
17. Li X, Makarov SS. An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes. Proc Natl Acad Sci USA. 2006 103 : 17432 17437.
18. Tas SW, Vervoordeldonk MJ, Hajji N, et al. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther. 2006 8 : R86.
19. Tas SW, Hajji N, Stenvers DJ, et al. Reduction of proinflammatory cytokine expression in the synovium by targeting IKKbeta in vivo in a rat model. Arthritis Rheum. 2006 54 : 3716 3718.
20. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sul-fate. Osteoarthritis Cartilage. 2008 16 : S14 8.
21. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 354 : 795 808.
22. Omata T, Itokazu Y, Inoue N, et al. Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis. Arzneimittelforschung. 2000 50 : 148 153.
23. Lauder SN, Carty SM, Carpenter CE, et al. Interleukin-1beta induced activation of nuclear factor-kappab can be inhibited by novel pharmacological agents in osteoarthritis. Rheumatology. 2007 46 : 752 758.
24. Saklatvala J. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets. 2007 8 : 305 313.
25. Xu H, He Y, Yang X, et al. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology. 2007 46 : 920 926.
26. Alvarez-Soria MA, Largo R, Santillana J, et al. Differential anticatabolic profile of glucosamine sulfate versus other antios-teoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblast in culture. Osteoarthritis Cartilage. 2005 13 : S153.27.
27. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002 10 : 768 777.
28. Monfort J, Pelletier J P, Garcia-Giralt N, et al. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Ann Rheum Dis. 2008 67 : 735 740.
29. Tat SK, Pelletier J P, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis sub-chondral bone osteoblasts: a basic science study. Arthritis Res Ther. 2007 9 : R117.
30. Kwan Tat S, Pelletier JP, Lajeunesse D, et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol. 2008 26 : 295 304.
31. Tsubaki M, Kato C, Manno M, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem. 2007 304 : 53 60.
32. Barker SA, Hawkins CF, Hewins M. Mucopolysaccharides in synovial fluid detection of chondroitin sulphate. Ann Rheum Dis. 1966 25: 209 213.
33. Lewis S, Crossman M, Flannelly J, et al. Chondroitin sulphation patterns in synovial fluid in osteoarthritis subsets. Ann Rheum Dis. 1999 58: 441 445.
34. Aigner T, Sachse A, Gebhard PM, et al. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev. 2006 58: 128 149.
35. Forsyth CB, Pulai J, Loeser RF. Fibronectin fragments and blocking antibodies to alpha2beta1 and alpha5beta1 integrins stimulate mitogen-activated protein kinase signaling and increase collage-nase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum. 2002 46: 2368 2376.
36. Homandberg GA, Costa V, Wen C. Fibronectin fragments active in chondrocytic chondrolysis can be chemically cross-linked to the alpha5 integrin receptor subunit. Osteoarthritis Cartilage. 2002 10: 938 949.
37. Reyes CD, Petrie TA, Garcia AJ. Mixed extracellular matrix ligands synergistically modulate integrin adhesion and signaling. J Cell Physiol. 2008 217: 450 458.
38. Loeser RF. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 2006 54: 1357 1360.
39. Li Y, Xu L, Olsen BR. Lessons from genetic forms of osteoarthritis for the pathogenesis of the disease. Osteoarthritis Cartilage. 2007 15: 1101 1105.
40. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol. 2006 20: 1003 1025.
41. Luyten FP, Lories RJ, Verschueren P, et al. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol. 2006 20: 829 848.
42. Ge Z, Hu Y, Heng BC, et al. Osteoarthritis and therapy. Arthritis Rheum. 2006 55: 493 500.
43. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res. 1999 40: 1 11.
44. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multi-center study versus placebo. Osteoarthritis Cartilage. 2004 12: 269 276.
45. Mazieres B, Combe B, Phan Van A, et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 2001 28: 173 181.
46. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998 6: 39 46.
47. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002 21: 231 243.
48. Rovetta G, Monteforte P, Molfetta G, et al. Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React. 2002 24: 29 32.
49. Volpi N. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. Curr Drug Targets Immune Endocr Metabol Disord. 2004 4: 119 127.
50. Legendre F, Bauge C, Roche R, et al. Chondroitin sulfate modulation of matrix and inflammatory gene expression in IL-1beta-stimulated chondrocytes-study in hypoxic alginate bead cultures. Osteoarthritis Cartilage. 2008 16: 105 114.
51. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999 18: 6853 6866.
52. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol. 2008 75: 1567 1579.
53. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene. 2006 25: 6831 6843.
54. Montell E, Iovu M, Héroux L, et al. Chronic administrationof chondroitin sulfate does not affect cytochrome P450 nor NADPH P450 reductase. Osteoarthritis Cartilage. 2008 16: S226 7.
55. Bell S, Degitz K, Quirling M, et al. Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal. 2003 15: 1 7.
56. Westergaard M, Henningsen J, Johansen C, et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol. 2003 121: 1104 1117.
57. Abdou AG, Hanout HM. Evaluation of sur-vivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol. 2008 35: 445 451.
58. Johansen C, Flindt E, Kragballe K, et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional pso-riatic skin. J Invest Dermatol. 2005 124: 1284 1292.
59. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003 21: 392 397.
60. Yano S, Banno T, Walsh R, et al. Transcriptional responses of human epidermal keratinocytes to cytokine inter-leukin-1. J Cell Physiol. 2008 214: 1 13.
61. Li H, Gao L, Shen Z, et al. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res. 2008 300: 425 433.
62. Lizzul P F, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005 124: 1275 1283.
63. Wildfeuer A. [6-hydroxy-1,3-ben-zoxathiol- 2-one, an antipsoriatic with antibacterial and antimycotic properties]. Arzneimittelforschung. 1970 20: 824 831.
64. Kim MH, Lee HY, Roh E, et al. Novel imi-nobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide- activated macrophages. Biochem Pharmacol. 2008 76: 373 381.
65. Amigo M, Paya M, De Rosa S, et al. Antipsoriatic effects of avarol-3'-thiosalicy-late are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. Br J Pharmacol. 2007 152: 353 365.
66. Meili-Butz S, Niermann T, Fasler-Kan E, et al. Dimethyl fumarate, a small molecule drug for psoriasis, inhibits nuclear factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol. 2008 586: 251 258.
67. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008 65: 1631 1652.
68. Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. Br J Dermatol. 2005 153: 725 732.
69. Vergés J, Montell E, Herrero M, et al. Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sul-fate: report of 3 cases. Med Clin. 2004 123: 739 742.
70. Verges J, Montell E, Herrero M, et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005 11: 31.
71. Kurita H. Über den einfluss des chon-droitin sulfates auf die experimentelle ath-erosklerose in kaninchen. Med J Shinshu University. 1955 1: 23 7.
72. Murata K. Infra-red spectroscopic evidence of chondroitin polysulphate and its relation to anticoagulant activity. Nature. 1962 193: 578 579.
73. Murata K. The effects of sulfated polysac-charides obtained from seaweeds on experimental atherosclerosis. J Gerontol. 1962 17: 30 6.
74. Nakamura M, Ishihara Y, Sata T, et al. Acid mucopolysaccharides and lipids of Japanese arteries, with special reference to the absence of hyaluronic acid in Japanese cerebral artery. J Atheroscler Res. 1966 6: 132 150.
75. Morrison LM. Response of ischemic heart disease to chondroitin sulfate-A. J Am Geriatr Soc. 1969 17: 913 923.
76. Morrison LM, Enrick N. Coronary heart disease: reduction of death rate by chondroitin sulfate A. Angiology. 1973 24: 269 287.
77. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998 97: 1671 1674.
78. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation. 1998 98: 839 844.
79. Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci. 2009 116: 219 230.
80. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 342: 836 843.
81. Gutierrez SH, Kuri MR, del Castillo ER. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets. 2008 8: 153 160.
82. Chung JH, Seo AY, Chung SW, et al. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res Rev. 2008 7: 126 136.
83. Steinhubl SR, Badimon JJ, Bhatt DL, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 2007 12: 113 122.
84. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Investig Med. 2006 54: 395 401.
85. Montecucco F, Steffens S, Mach F. The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol. 2007 2007: 75805.
86. Herrero-Beaumont G, Marcos ME, Sanchez-Pernaute O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol. 2008 154: 843 851.
87. Largo R, Sanchez-Pernaute O, Marcos ME, et al. Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. Arthritis Rheum. 2008 58: 2723 2734.
88. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis. 1999 10: S9 12.
89. Zhang SZ, Zhao XH, Zhang DC. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol. 2006 3: 35 40.
90. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008 263 : 591 596.
91. Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig Liver Dis. 2008 40 : S225 8.
92. Ferrero-Miliani L, Nielsen OH, Andersen PS, et al. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol. 2007 147 : 227 235.
93. Harris G, KuoLee R, Chen W. Role of Tolllike receptors in health and diseases of gastrointestinal tract. World J Gastroenterol. 2006 12 : 2149 2160.
94. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator- activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis. 2002 8 : 330 339.
95. Takaki K, Mitsuyama K, Tsuruta O, et al. Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res. 2006 55 : 10 5.
96. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 134 : 688 695.
97. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998 42 : 477 484.
98. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999 353 : 459 461.
99. Zheng P, Niu FL, Liu WZ, et al. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J Gastroenterol. 2005 11 : 4912 4915.
100. Islam MS, Murata T, Fujisawa M, et al. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br J Pharmacol. 2008 154 : 812 824.
101. Egan LJ, Toruner M. NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach. Ann N Y Acad Sci. 2006 1072 : 114 122.
102. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008 CD006893.
103. Wilhelm SM, McKenney KA, Rivait KN, et al. A review of infliximab use in ulcera-tive colitis. Clin Ther. 2008 30 : 223 230.
104. Hori Y, Hoshino J, Yamazaki C, et al. Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol. 2001 85 : 155 160.
105. Ota S, Yoshihara S, Ishido K, et al. Effects of proteoglycan on dextran sulfate sodium-induced experimental colitis in rats. Dig Dis Sci. 2008 53 : 3176 3183.
106. Yomogida S, Kojima Y, Tsutsumi-Ishii Y, et al. Glucosamine, a naturally occurring amino monosaccharide, suppresses dex-tran sulfate sodium-induced colitis in rats. Int J Mol Med. 2008 22 : 317 323.
107. Rogers J, Mastroeni D, Leonard B, et al. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol. 2007 82 : 235 246.
108. Memet S. NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol. 2006 72 : 1180 1195.
109. Sriram K, O'Callaghan JP. Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol. 2007 2 : 140 153.
110. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003 112 : 440 449.
111. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 1 : 279 284.
112. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 289 : 2819 2826.
113. Luna-Medina R, Cortes-Canteli M, Alonso M, et al. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem. 2005 280 : 21453 21462.
114. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006 6 : 246 254.
115. Bright JJ, Kanakasabai S, Chearwae W, et al. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res. 2008 2008 : 658520.
116. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem. 2008 106 : 506 518.
117. Jones LL, Yamaguchi Y, Stallcup WB, et al. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J Neurosci. 2002 22 : 2792 2803.
118. Grimpe B, Silver J. The extracellular matrix in axon regeneration. Prog Brain Res. 2002 137 : 333 349.
119. Rhodes KE, Fawcett JW. Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat. 2004 204 : 33 48.
120. Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 2008 5 : e171.
121. Rolls A, Avidan H, Cahalon L, et al. A dis-accharide derived from chondroitin sulphate proteoglycan promotes central nervous system repair in rats and mice. Eur J Neurosci. 2004 20 : 1973 1983.
122. Rolls A, Cahalon L, Bakalash S, et al. A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurode-generation. FASEB J. 2006 20 : 547 549.
123. Ebert S, Schoeberl T, Walczak Y, et al. Chondroitin sulfate disaccharide stimulates microglia to adopt a novel regulatory phenotype. J Leukoc Biol. 2008 84 : 736 740.
124. Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci. 2009 10 : 235 241.
125. van Horssen J, Wesseling P, van den Heuvel LP, et al. Heparan sulphate proteo-glycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003 2 : 482 492.
126. Aisen PS, Saumier D, Briand R, et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006 67 : 1757 1763.
127. Canas N, Valero T, Villarroya M, et al. Chondroitin sulfate protects SH-SY5Y cells from oxidative stress by inducing heme oxygenase-1 via phosphatidylinositol 3-kinase/Akt. J Pharmacol Exp Ther. 2007 323 : 946 953.
128. Ancelin ML, Christen Y, Ritchie K. Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement Geriatr Cogn Disord. 2007 24 : 1 19.
129. Vafeiadou K, Vauzour D, Spencer JP. Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets. 2007 7 : 211 224.
130. Schwartz M. Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches. Eur J Ophthalmol. 2001 11 : S7 11.
131. Bakalash S, Rolls A, Lider O, et al. Chondroitin sulfate-derived disaccharide protects retinal cells from elevated intraocular pressure in aged and immunocompromised rats. Invest Ophthalmol Vis Sci. 2007 48 : 1181 1190.
132. Ronca F, Palmieri L, Panicucci P, et al. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 6 : 14 21.
133. Theoharides TC, Kempuraj D, Kourelis T, et al. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci. 2008 1144 : 74 82.
134. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol. 2008 28 : 660 670.
135. Montes M, Zhang X, Berthelot L, et al. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin Immunol. 2009 130 : 133 144.
136. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflamma-tory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998 160 : 3513 3521.
137. Martel-Pelletier J, Mineau F, Jovanovic D, et al. Mitogen-activated protein kinase and nuclear factor kappaB together regulate interleukin-17- induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated proten kinase (MAPKAPK). Arthritis Rheum. 1999 42 : 2399 2409.
138. Gveric D, Kaltschmidt C, Cuzner ML, et al. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol. 1998 57 : 168 178.
139. Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol. 1999 155 : 1433 1438.
140. Satoh J, Misawa T, Tabunoki H, et al. Molecular network analysis of T-cell tran-scriptome suggests aberrant regulation of gene expression by NF-kappaB as a bio-marker for relapse of multiple sclerosis. Dis Markers. 2008 25 : 27 35.
141. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001 294 : 1731 1735.
142. Masilamoni JG, Jesudason EP, Baben B, et al. Molecular chaperone alpha-crystallin prevents detrimental effects of neuroin-flammation. Biochim Biophys Acta. 2006 1762 : 284 293.
143. van Noort JM, van Sechel AC, Bajramovic JJ, et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature. 1995 375 : 798 801.
144. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyeli-nation. Nature. 2007 448 : 474 479.
145. Sakai S, Akiyama H, Harikai N, et al. Effect of chondroitin sulfate on murine splenocytes sensitized with ovalbumin. Immunol Lett. 2002 84 : 211 216.
146. Sakai S, Akiyama H, Sato Y, et al. Chondroitin sulfate intake inhibits the IgE-mediated allergic response by down-regulating Th2 responses in mice. J Biol Chem. 2006 281 : 19872 19880.
147. Marusic S, Thakker P, Pelker JW, et al. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J Neuroimmunol. 2008 204 : 29 37.
148. Chan PS, Caron JP, Orth MW. Effect of glu-cosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res. 2005 66 : 1870 1876.
149. Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J Suppl. 2002 224 229.
150. Zhang GX, Yu S, Gran B, et al. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response. J Immunol. 2005 175 : 7202 7208.
151. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 2008 10 : 212.
152. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol. 2006 72 : 1161 1179.